⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7474747 | 0.75 | — | — | |
| SCHEMBL7338687 | 0.74 | — | — | |
| SCHEMBL2571540 | 0.74 | — | — | |
| SCHEMBL2072178 | 0.73 | CYP2C9 (0.35) | — | |
| SCHEMBL2072181 | 0.73 | CYP2C9 (0.35) | — | |
| SCHEMBL191998 | 0.71 | — | — | |
| SCHEMBL285299 | 0.71 | — | — | |
| SCHEMBL13889160 | 0.71 | — | — | |
| SCHEMBL36515 | 0.71 | — | — | |
| SCHEMBL19645307 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110114358-B | Novel compound and pharmacologically acceptable salt thereof | 明治制果药业株式会社 | 2021-12-03 | — | — | CN | disclosed |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| EP-3560925-B1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO LTD (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3815687-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Meiji Seika Pharma Co., Ltd. (JP) | 2021-05-05 | — | — | EP | disclosed |
| CN-112312914-A | Therapeutic agent for inflammatory disease, autoimmune disease, fibrotic disease, and cancer disease | 明治制果药业株式会社 | 2021-02-02 | — | — | CN | disclosed |
| CN-106661355-B | Ink composition, inkjet recording method, and colored body | 日本化药株式会社 | 2020-06-12 | — | — | CN | disclosed |
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-06-02 | — | — | US | disclosed |
| US-10544320-B2 | Ink composition, inkjet recording method, and colored article | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2020-01-28 | — | — | US | disclosed |
| WO-2020004521-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2020-01-02 | — | — | WO | disclosed |
| EP-3560925-A1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3153555-B1 | INK COMPOSITION, INKJET RECORDING METHOD, AND COLORED ARTICLE | NIPPON KAYAKU KK (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-20170137652-A1 | INK COMPOSITION, INKJET RECORDING METHOD, AND COLORED ARTICLE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2017-05-18 | — | — | US | disclosed |
| EP-3153555-A1 | INK COMPOSITION, INKJET RECORDING METHOD, AND PRINT ARTICLE | Nippon Kayaku Kabushiki Kaisha (JP) | 2017-04-12 | — | — | EP | disclosed |
| EP-2681195-A1 | NOVEL KINASE INHIBITORS | Novartis AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012120428-A1 | NOVEL KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| EP-2382972-A1 | Methods for preventing and treating neurodegenerative disorders | Boehringer Ingelheim International GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100081625-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| EP-2124965-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008090210-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | WO | disclosed |